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Abstract 25 
Alzheimer’s disease (AD) and chronic cerebral hypoperfusion (CCH) often coexist in 26 
dementia patients in aging societies. The hallmarks of AD including amyloid-β 27 
(Aβ)/phosphorylated tau (pTau) and pathology-related events such as neural oxidative stress 28 
and neuroinflammation play critical roles in pathogenesis of AD with CCH. A large number of 29 
lessons from failures of drugs targeting a single target or pathway on this so complicated disease 30 
indicate that disease-modifying therapies targeting multiple key pathways hold potent potential 31 
in therapy of the disease. In the present study, we used a novel mouse model of AD with CCH 32 
to investigate a potential therapeutic effect of a free radical scavenger, Edaravone (EDA) on 33 
AD with CCH via examining motor and cognitivie capacity, AD hallmarks, neural oxidative 34 
stress, and neuroinflammation. Compared with AD with CCH mice at 12 months of age, EDA 35 
significantly improved motor and cognitive deficits, attenuated neuronal loss, reduced Aβ/pTau 36 
accumulation, and alleviated neural oxidative stress and neuroinflammation. These findings 37 
suggest that EDA possesses clinical and pathological benefits for AD with CCH in the present 38 
mouse model and has a potential as a therapeutic agent for AD with CCH via targeting multiple 39 
key pathways of the disease pathogenesis.  40 
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Introduction 47 
Based on epidemiological analysis, Alzheimer’s disease (AD) and cerebrovascular disease 48 
often coexist in dementia patients [1]. Our recent data indicated that 69% of the dementia 49 
patients who are over 75 years old suffer from AD [2], approximately 90% of whom have 50 
cerebrovascular disease [2, 3]. In cerebrovascular diseases, chronic cerebral hypoperfusion 51 
(CCH) is ubiquitous in the elderly AD patients [4-6], and could play pivotal roles in triggering 52 
and exacerbating the pathophysiological progress of AD which could be related to Aβ 53 
overproduction and accumulation [7], Aβ clearance impairment [8], Tau-hyperphosphorylation 54 
[9], neuroinflammation [10], neural oxidative stress [7], and neuronal loss [11, 12]. 55 
Despite massive progress has been made for discovering the pathogenesis of AD or AD 56 
with CCH in the recent years [13-15], No efficient disease-modifying therapeutics for AD or 57 
AD with CCH are available in clinic at present [16, 17]. According to recent lessons learnt that 58 
a therapy targeting a single protein or pathway does not have therapeutic effects on such a 59 
complex disease [17], it is necessary to discover a novel drug which can target multiple key 60 
pathways in the shared pathogenesis of AD with CCH.  61 
Edaravone (3-methyl-1-phenyl-2pyrazoline-5-one, EDA), an oxygen radical scavenger is 62 
widely used for the treatment of acute cerebral ischemia patients [18] and amyotrophic lateral 63 
sclerosis (ALS) patients [19] owing to its anti-oxidative stress and anti-inflammation effects. 64 
Oxidative stress is a shared manifestation of AD and CCH accelerating pathogenesis including 65 
Aβ deposition, Tau-hyperphosphorylation, and inflammatory response [7, 18, 20]. Both Aβ and 66 
CCH can induce the generation of reactive oxygen species (ROS) [21, 22]. ROS is one of the 67 
crucial factors promoting the pathological progression of AD via aggregating the toxicity of Aβ 68 
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and CCH-driven vicious cycles [23, 24]. Previous studies showed that EDA not only had 69 
inhibition effects on multiple key AD pathways including Aβ, Tau-hyperphosphorylation, 70 
neuroinflammation, neural oxidative stress, and neuronal loss via scavenging both ROS and Aβ 71 
in a family AD mouse model [25] but also alleviated Aβ or streptozotocin-induced cognitive 72 
impairment via anti-oxidative stress and anti-inflammationin in rat models [26, 27] or in in-73 
vitro models [28, 29]. Moreover, recent experimental studies also found that EDA could 74 
attenuate cognitive deficits via inhibiting oxidative stress induced by CCH in rat models [18, 75 
30]. 76 
Therefore, in the present study, we applied a novel AD plus CCH mouse model for 77 
investigating the effects of EDA on the AD with CCH-type pathologies and behavior deficits.      78 
 79 
Materials and Methods 80 
Experimental model and drug treatment 81 
All animal experiments were performed in compliance with a protocol approved by the 82 
Animal Committee of the Graduate School of Medicine and Dentistry, Okayama University 83 
(OKU#2012325). Male mice were randomly divided into 4 groups: wild type (WT) group (WT 84 
+ sham surgery, n=10), APP23 group (APP23 + sham surgery, n=12), chronic cerebral 85 
hypoperfusion (CCH) group (APP23 + CCH, n=8), and edaravone (EDA)-treated group 86 
(APP23 + CCH + EDA, n=10). Transgenic mouse APP23 was previously described as the 87 
generation of the B6, D2-TgN (Thy1-APPSwe). Ameroid constrictors (0.75mm internal 88 
diameter; Research Instruments NW, Lebanon, OR, USA) was applied to induce CCH. In order 89 
to conduct a surgery of CCH, experimental mice were subjected to cervical incision, and 90 
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ameroid constrictors were applied to bilateral common carotid arteries (BCCAs) at 4 months 91 
(M) of age in the APP23 + CCH and APP23 + CCH + EDA groups. After the surgery, a single 92 
intraperitoneal injection of edaravone (50mg/kg; 3mg/ml; Mitsubishi Tanabe Pharmaceutical 93 
Co. Ltd.,) began to be administrated into mice in the APP23 + CCH + EDA group every other 94 
day till sacrifice at 12 M. 95 
Cerebral blood flow (CBF) was measured with a laser-Doppler flowmeter (FLO-C1, 96 
Omegawave, Tokyo, Japan) before and 1, 3, 7, 14 and 28 d after the surgery. A laser Doppler 97 
flowmetry probe was fixed perpendicular to the skull 1 mm posterior and 2.5 mm lateral to the 98 
bregma where CBF values were measured five times. The mean CBF value was recorded. 99 
Behavioral analysis 100 
    The rotarod test was performed to evaluate motor coordination and balance at 2, 5, 7, 9, 101 
11 M-old mice by measuring latency seconds (s), as previously described [10, 31]. Rotarod 102 
speed was accelerated from 4 to 40 rpm over a 5-minute period. The latency seconds were 103 
recorded when 5 minutes had arrived or mice had fallen from a rotating drum (MK670; 104 
Muromachi Kikai Co., Tokyo, Japan). The test was repeated 5 times with an interval of 5 105 
minutes between each trial. 106 
An 8-arm radial maze test was used to evaluate behavioral memory (mainly for working 107 
memory) described according to our and other’s reports [32, 33, 10]. In brief, each mouse was 108 
conducted a food deprivation with a schedule designed to maintain the deficiency of body 109 
weight within 10% and free access to water during 8-arm trials. For acquisition trials, maze 110 
adaptation was performed once a day in 5 consecutive days before formal trials. Five mice were 111 
allowed to explore the 8-arm maze only once for 5 minutes. Food pellets were randomly 112 
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scattered over the entire maze surface. For each formal trial, a mouse was allowed to freely 113 
make arm choices. When all four pellets had been eaten or 5 min had elapsed, the number of 114 
re-entries into the baited arms previously visited was recorded as a working memory error index. 115 
The radial maze task was performed separately when mice were 3, 6, 8, 10, and 12 M old. 116 
Tissue preparation and immunohistochemistry 117 
At 12 M of age, 4 mice groups were deeply anesthetized by intraperitoneal injection of 118 
pentobarbital (40mg/kg), and transcardially perfused with 20 ml of ice-cold phosphate-buffered 119 
saline (PBS) and then 20 ml of ice-cold 4% paraformaldehyde (PFA) in 0.1 mol/L phosphate 120 
buffer. The brains were removed and post-fixed in 4% PFA overnight. 50-µm-thick floating 121 
coronal sections were sliced with a vibrating blade microtome (LEICA VT1000S; Leica, 122 
Nussloch, Germany). The morphological and pathological changes were detected in the 123 
cerebral cortex (CTX), hippocampus (HI), thalamus (TH) in this study. For Nissl staining, brain 124 
sections were immersed in 0.1% cresyl violet for 5 min at room temperature, and then were 125 
dehydrated in graded alcohol, and coverslipped with microcoverglass. For single 126 
immunohistochemistry, brain sections were immerses in 0.6% periodic acid to block intrinsic 127 
peroxidase, and were treated with 5% bovine serum in 50mM PBS, pH 7.4, containing 0.1% 128 
triton to block any non-specific antibody responses then were incubated with primary 129 
antibodies. The amino acid sites were probed with the following antibodies: Aβ oligomer (1:200, 130 
F11G3; Millipore), 6E10 (1:1000, SIG-39320; Biolegend), pTau (1:200, ab64193; Abcam), 3-131 
NT (1:200, ab61392; Abcam), AGE (1:1000, ab23722; Abcam), Iba-1 (1:1000, NCNP24; 132 
Wako), IL-1β (1:100; R&D System; AF-401-NA), NLRP3 (1:200, ab4207; Abcam), and 133 
negative control was obtained without primary antibody. Immunoreactions were visualized 134 
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using horseradish peroxidase-conjugated antibody with the diaminobenzidine reaction. 135 
Detection and analyses 136 
The above mentioned immunohistochemistry sections were digitized with a digital 137 
microscope camera (Olympus BX-51; Olympus Optical Co, Japan). Three levels of sections 138 
are from the caudate putamen (1.0, 0.5, and 0 mm rostal to the bregma) per brain and 3 or 4 139 
randomly regions were selected to take photos for analysis per section (i.e., n=9-12 140 
measurements per mouse). For the semiquantitative evaluation of Nissl, Aβ oligomer, pTau, 3-141 
NT, AGE, Iba-1, IL-1β, and NLRP3 staining, the average pixel intensity of signal in the CTX, 142 
HI, and TH were measured. For 6E10-positive Aβ deposit analysis, data were reported as the 143 
percentage area occupied by the 6E10-positive signal in the CTX, HI, and TH. All 144 
immunostaining data were analyzed by image processing software (Image J; National Institutes 145 
of Health, Bethesda, USA). 146 
Statistical analysis 147 
All results were presented as mean ± SD. Statistical comparisons of LDF, rotarod test, and 148 
8-arm test were performed using repeated measures analysis of variance (ANOVA) based on a 149 
Bonferroni's post hoc comparison. Other comparisons between two groups were tested using 150 
Mann-Whitney u test and among three or over three groups were tested using one way ANOVA 151 
based on a Tukey-Kramer post comparison. p < 0.05 was considered statistically significant. 152 
 153 
Results 154 
Edaravone partially recovers cortical surface CBF in AD mice with CCH 155 
The level of CBF in APP23 group did not significantly dropped at 1 d, 3 d, 7 d, 14 d and 156 
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28 d after sham surgery (Fig. 1A, triangles). However, CBF gradually and progressively 157 
decreased in both APP23 + CCH and APP23 + CCH +EDA groups from 1 d after surgery (Fig. 158 
1A, dotted squares and filled squares). More importantly, compared with APP23 group, the 159 
level of CBF in APP23 + CCH and APP23 + CCH +EDA groups significantly reduced at 1 d, 160 
3 d, 7 d, 14 d and 28 d after sham surgery (Fig. 1A, #p<0.05 VS APP23, ##p<0.01 VS APP23). 161 
On the other hand, CBF in APP23 + CCH + EDA group significantly recovered at 7 d in relative 162 
to that in APP23 + CCH group, however, the value of CBF did not significantly increase at 163 
other time points but had a trend of recovery in APP23 + CCH + EDA group (Fig. 1A, &p<0.05 164 
VS APP23 + CCH, &&p<0.01 VS APP23 + CCH).   165 
Edaravone improves motor and cognitive deficits in AD mice with CCH 166 
Rotarod and 8-arm radial maze tests showed no significant difference between wild type 167 
and APP23 groups at 2 M and 3 M before CCH surgery (Fig. 1B). The rotarod test demonstrated 168 
that latency was significantly shorter in APP23 + CCH group compared to WT group at 5, 7, 9 169 
and 11 M (Fig. 1B, *p<0.05 vs WT, **p<0.01 vs WT), and in relative to APP23 group, APP23 170 
+ CCH group also showed a significantly inferior performance at a few blocks at 5, 7, 9 and 11 171 
M (Fig. 1B, #p<0.05 vs APP23, ##p<0.01 vs APP23), indicating that motor deficits 172 
significantly existed in APP23 + CCH group at 5, 7, 9 and 11 M in our experiment. Moreover, 173 
motor performance was significantly recovered after EDA administration compared with 174 
APP23 + CCH group at a few blocks at 5, 7, 9 and 11 M (Fig. 1B, &p<0.05 VS APP23 + CCH), 175 
indicating that EDA could have an effect on the recovery of motor deficits in APP23 mice after 176 
CCH. 177 
The 8-arm radial maze was used to examine working memory impairment. In APP23 + 178 
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CCH group, the revisiting error (used as an indicator of spatial working memory) was not 179 
significantly different among the four mice groups at 6 M (Fig. 1C). But, APP23 + CCH group 180 
showed marked difference in the number of revisiting errors in relative to WT and APP23 group 181 
at some blocks at 8, 10 and 12 M (Fig. 1C, **p<0.01 vs WT; #p<0.05 vs APP23, ##p<0.01 vs 182 
APP23). Moreover, the number of revisiting errors is dramatically decreased at some blocks at 183 
8, 10 and 12 M in APP23 + CCH + EDA group in comparison with APP23 + CCH group (Fig. 184 
1C, &p<0.05 VS APP23 + CCH, &&p<0.01 VS APP23 + CCH). These results indicated that 185 
spatial working memory was impaired in APP23 + CCH mice at 8, 10 and 12 M. However, 186 
EDA administration could rescue such impairment in spatial working memory.  187 
Edaravone inhibits neuropathologic changes in AD mice with CCH 188 
Nissl staining was used to examine neuropathologic changes in the cortex (CTX), cornu 189 
ammonis 1 (CA1), cornu ammonis 3 (CA3), dentate gyrus (DG), and thalamus (TH) of four 190 
group mice (Fig. 2A). Analysis of pixel intensity demonstrated a significant difference exist in 191 
the CA1, CA3, and DG of APP23 mice in relative to WT mice (Fig. 2B, *p<0.05 vs WT), 192 
moreover, compared to APP23 group at 12 M, Nissl staining intensity in APP23 + CCH group 193 
significantly decreased in the above 5 regions at 12 M (Fig. 2B, #p<0.05 vs APP23, ##p<0.01 194 
vs APP23). The dramatic decrease of Nissl staining intensity was significantly recovered in the 195 
CTX, CA1, CA3 and TH regions at 12 M by EDA treatment (Fig. 2B, &p<0.05 VS APP23 + 196 
CCH, &&p<0.01 VS APP23 + CCH).    197 
Edaravone reduces the expression of Aβ oligomer in AD mice with CCH 198 
Aβ oligomer was labeled in the membrane and cytoplasm of cells in various brain regions, 199 
including the CTX, CA1, CA3, DG, and TH (Fig. 3A). Quantitative analysis of the pixel 200 
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intensity of Aβ oligomer-positive cells showed that the ratio of pixel intensity relative to WT 201 
group was significantly increased in the CTX, CA1, CA3, DG, TH of APP23 mice at 12 M (Fig. 202 
3B, **p<0.01 vs WT). Moreover, APP23 + CCH group showed a great increase of the ratio of 203 
pixel intensity of Aβ oligomer-positive cells in the above 5 regions compared to APP23 group 204 
(Fig. 3B, ##p<0.01 vs APP23). These increases were significantly reduced by EDA 205 
administration (Fig. 3B, &&p<0.01 VS APP23 + CCH). 206 
Edaravone reduces Aβ burden in AD mice with CCH 207 
To determine the temporal expression of all forms of Aβ, we examined Aβ accumulation 208 
in the CTX, HI, and TH regions using antibody 6E10 which detects all forms of Aβ. Few 6E10-209 
positive Aβ accumulation were observed in the CTX, HI, and TH of APP23 mice at 12 M (Fig. 210 
3C). However, the regions of these Aβ accumulations considerably increased in APP23 + CCH 211 
group (Fig. 3D, ##p<0.01 vs APP23), and EDA administration significantly reduced 6E10-212 
positive Aβ accumulations in the CTX, HI, and TH regions at 12 M (Fig. 3D, &&p<0.01 VS 213 
APP23 + CCH). 214 
Edaravone attenuates Tau-phosphorylation in AD mice with CCH 215 
pTau was labeled in the cytoplasm of neural cells in the CTX, CA1, CA3, DG, and TH 216 
(Fig. 4A). Quantitative analysis of the pixel intensity of pTau-positive cells indicated that the 217 
ratio of pixel intensity relative to WT group was significantly increased in the CTX, CA3, DG, 218 
TH of APP23 mice at 12 M (Fig. 4B, **p<0.01 vs WT). Furthermore, the ratio of pixel intensity 219 
of pTau-positive cells significantly increased in the above 5 regions of APP23 + CCH mice 220 
compared to APP23 group (Fig. 4B, ##p<0.01 vs APP23). Such increases were significantly 221 
attenuated by EDA administration (Fig. 4B, &p<0.05 VS APP23 + CCH, &&p<0.01 VS APP23 222 
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+ CCH). 223 
Edaravone ameliorates neural oxidative stress in AD mice with CCH 224 
We performed studies on oxidative stress markers in the CTX, CA1, CA3, DG, and TH 225 
regions among 4 group mice. 3-NT as a protein peroxidation production was clearly and mainly 226 
labeled in the cytoplasm of cells in above regions at 12 M (Fig. 5A). Quantitative analysis 227 
showed the level of 3-NE significantly increased in the CTX, CA1, CA3 and TH regions of 228 
APP23 mice at 12 M in relative to WT mice, and the level of 3-NT was significantly reduced 229 
in the above 5 regions of EDA-administrated mice compared with APP23 + CCH mice which 230 
showed a significantly higher level of 3-NT intensity in the above 5 regions in comparison with 231 
APP23 mice at 12 M (Fig. 5B, **p<0.01 VS WT; #p<0.05 VS APP23, ##p<0.01 VS APP23; 232 
&p<0.05 VS APP23 + CCH, &&p<0.01 VS APP23 + CCH). Furthermore, AGE as a major 233 
product of oxidative degradation of glycated proteins and unsaturated fatty acids was clearly 234 
and mainly labeled in the cytoplasm of cells at 12 M (Fig. 5C). We found that the pixel intensity 235 
of AGE-positive signals significantly increased in the CTX, CA1, CA3, DG, and TH regions at 236 
12 M comparing WT group with APP23 group, and comparing APP23 group and APP23 + 237 
CCH group (Fig. 5D, **p<0.01 VS WT; ##p<0.01 VS APP23). More importantly, EDA 238 
administration could significantly ameliorate such increased level of AGE expression in the 239 
above 5 regions of APP23 + CCH at 12 M (Fig. 5D, &p<0.05 VS APP23 + CCH, &&p<0.01 240 
VS APP23 + CCH).        241 
Edaravone ameliorates neuroinflammation in AD mice with CCH 242 
The expression of Iba-1-positive microglial cells was clearly observed in the CTX, CA1, 243 
CA3, DG, and TH regions at 12 M (Fig. 6A). Quantitative analysis indicated the ratio of pixel 244 
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intensity in comparison with WT group was significantly increased in the above 5 regions of 245 
APP23 mice at 12 M, and APP23 + CCH group showed a remarkable increase of Iba-1-positive 246 
microglia intensity in the above 5 regions at 12 M in relative to APP23 mice (Fig. 6B, #p<0.05 247 
VS APP23, ##p<0.01 VS APP23; #p<0.05 VS APP23, ##p<0.01 VS APP2). EDA 248 
administration strongly ameliorate such activation of microglia in above regions at 12 M (Fig. 249 
6B, &p<0.05 VS APP23 + CCH, &&p<0.01 VS APP23 + CCH). 250 
IL-1β showed a strongly increased expression in the neural cytoplasm of three APP23 251 
groups, especially in APP23 + CCH group in the CTX, CA1, CA3, DG, and TH regions at 12 252 
M (Fig. 6C). Quantitative analysis demonstrated that the ratio of pixel intensity in APP23 group 253 
is significantly higher than that in WT group in the above 5 regions at 12 M, and APP23 mice 254 
with CCH presented the strongest expression of IL-1β-positive signals among three APP23 255 
groups in the above 5 regions at 12 M, which was greatly attenuated by EDA administration 256 
(Fig. 6D, *p<0.05 VS WT, **p<0.01 VS WT; #p<0.05 VS APP23, ##p<0.01 VS APP23; 257 
&p<0.05 VS APP23 + CCH, &&p<0.01 VS APP23 + CCH). 258 
The NLRP3 as an intracellular protein is an important part of inflammasome complexes, 259 
involving many chronic neurological diseases such as AD and CCH. In our present study, 260 
compared with WT group, the expression of NLRP3 displayed stronger positive signals in 261 
cellular cytoplasm of the CTX, CA1, CA3, DG, and TH regions in three APP23 groups at 12 262 
M (Fig. 6E). Analysis of pixel intensity showed a significantly increased expression of NLRP3 263 
in APP23 group compared to WT group in the above 5 regions at 12 M compared with WT 264 
group (Fig. 6F, *p<0.05 VS WT, **p<0.01 VS WT). Additionally, CCH dramatically 265 
accelerated the expression of NLRP3 in the above 5 regions of APP23 mice (Fig. 6F, #p<0.05 266 
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VS APP23, ##p<0.01 VS APP23). More importantly, our result showed that EDA 267 
administration could have an effect on ameliorating such increased expression in above regions 268 
at 12 M (Fig. 6F, &p<0.05 VS APP23 + CCH, &&p<0.01 VS APP23 + CCH).    269 
 270 
Discussion 271 
In the present study, we found that EDA can partly improved CBF, ameliorated 272 
neuropathologic damage, reduced Aβ/Tau-phosphorylation (pTau) aggregation, ameliorated 273 
neural oxidative stress and neuroinflammation, and, more importantly, improved motor and 274 
cognitive deficits in AD with CCH mice at 12 M, indicating that EDA as a free radical scavenger 275 
could be a potential drug for the treatment of AD with CCH commonly observed in the elder 276 
society worldwide. 277 
A free radical scavenger, EDA has been shown not only to improve the decrease of CBF 278 
and motor and cognitive deficits in rats with CCH [18] but also to ameliorate cognitive 279 
impairment in a familial AD mouse model [25]. In the present study, we first examined the 280 
effect of EDA on oligemia and behavioral deficits in an AD plus CCH mouse model that is first 281 
reported in our previous study [10]. The present AD plus CCH mouse model showed a slowly 282 
progressive decrease of CBF, which was partly recovered by EDA administration (Fig. 1), and 283 
analyses of behavior tests showed better both motor performance and cognitive performance in 284 
APP23 + AD + EDA group at 5, 7, 9, 11 M and 8, 10, 12 M, respectively (Fig. 1), indicating 285 
that EDA could have a potent effect on improving motor and cognitive deficits in AD with CCH 286 
mice. Next, we were determined to detect the effect of EDA administration on celluar and 287 
molecular changes which is involved in AD with CCH. In our previous study, CCH accelerated 288 
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motor and cognitive deficits with strong neuronal loss in APP23 mice at 12 M, which could be 289 
due to massive reactive oxygen species and inflammatory responses induced by Aβ/pTau 290 
toxiety and neuronal energy failure [34]. The present study showed that EDA had a strong 291 
neuroprotection on ameliorating neuronal loss in CTX, CA1, CA3, and TH regions of APP23 292 
+ CCH mice at 12 M (Fig. 2). According to previous papers, EDA could exert a neuroprotection 293 
via scavenging Aβ/pTau in AD animal models [25]. Moreover, massive Aβ/pTau accumulation 294 
is also a key manifestations of CCH disease [35]. Therefore, we suppose that EDA could 295 
alleviate neuronal loss and neurodegeration in AD with CCH mice through reducing Aβ/pTau 296 
expression. For verifying our hypothesis, we examined the effect of EDA on alterations of Aβ 297 
oligomer, total Aβ, and pTau expressions in APP23 + CCH mice at 12 M. The results show that 298 
EDA strongly ameliorated Aβ/pTau aggregation exacerbated by CCH in APP23 mice at 12 M 299 
(Figs. 3, 4). Furthermore, some previous studies showed that before or after the onset of 300 
Aβ/pTau deposition in the condition of CCH, neural oxidative stress and neuroinflammation 301 
progressively occur and dramatically accelerate the pathological progression of AD by inducing 302 
an abnormally multiple of Aβ/pTau expression [36-40]. Therefore, we examined the effect of 303 
EDA on neural oxidative stress and neuroinflammation in AD with CCH mice at 12 M by 304 
analysing changes of neural oxidative stress markers 3-NT (a protein peroxidation product) and 305 
AGE (an oxidative glycated product), and neuroinflammation markers Iba-1 (microglia), Il-1β 306 
(proinflammatory cytokines), and NLRP3 (inflammasome), respectively. The results (Figs. 5,6) 307 
indicated that EDA could dramatically suppress neural oxidative stress and neuroinflammation 308 
enhanced by CCH in APP23 mice at 12 M. Overall, EDA could improve motor and cognitive 309 
impairments by alleviating neuronal loss perhaps owing to its effect of decreasing Aβ/pTau 310 
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accumulations, neural oxidative stress, and neuroinflammation in APP23 + CCH mice model 311 
at 12 M.    312 
In summary, the present study demonstrated a strong potential of ischemic stroke drug 313 
EDA in the therapy for AD with CCH which is commonly observed in current elder societies 314 
woeldwide [41] by targeting multiple key pathways, including neuropathologic damage, 315 
Aβ/pTau aggregation, neuronal oxidative stress, and neuroinflammation, which presents a 316 
future research direction of disease-modifying therapy applied in AD with CCH by 317 
simultaneously inhibiting multiple cascades involving in disease pathogenesis. 318 
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Figure Legends 467 
Fig. 1. Temporal profiles of cerebral blood flow (CBF) in APP23 mice and APP23 mice after 468 
implantation of ameroid constrictors with or without edaravone (EDA) administration. The 469 
levels of CBF at indicated time points (pre-operation, and 1, 3, 7, 14, 28 days after each surgery) 470 
are shown as percentage of the baseline CBF (A). EDA administration attenuates cerebral 471 
chronic hypoperfusion (CCH)-induced motor and memory deficits (B and C). Motor (Rotarod) 472 
and memory (8-arm radial maze) functions before and after CCH. Mean time of the latency 473 
indicates motor capacity in rotarod test. Note progressively inferior motor performances in the 474 
APP23 + CCH group than in the wild type (WT) group and APP23 group (B). The mean number 475 
of re-entry choices indicates working memory capacity in 8-arm test. Note gradually increased 476 
errors in the APP23 + CCH group that in the WT group and APP23 group (C). EDA 477 
administration dramatically rescued such motor and memory deficits (B and C) (*p<0.05 vs 478 
WT, **p<0.01 vs WT; #p<0.05 vs APP23, ##p<0.01 vs APP23; &p<0.05 VS APP23 + CCH, 479 
&&p<0.01 VS APP23 + CCH). 480 
 481 
Fig. 2. EDA inhibits neuronal loss in AD + CCH mice at 12 M. Representative 482 
photomicrographs of nissl staining in the cerebral cortex (CTX), cornu ammonis 1 (CA1), cornu 483 
ammonis 3 (CA3), dentate gyrus (DG), and thalamus (TH) at 12 M (A). Quantitative analysis 484 
of nissl staining intensity in the CTX, CA1, CA3, and TH at 12 M (B) (*p<0.05 vs WT; #p<0.05 485 
vs APP23, ##p<0.01 vs APP23; &p<0.05 VS APP23 + CCH, &&p<0.01 VS APP23 + CCH. 486 
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Scale bar=50 µm).   487 
 488 
Fig. 3. EDA reduces the expression of Aβ oligomer in APP23 + CCH mice at 12 M. 489 
Representative photomicrographs of Aβ oligomer (A) and quantitative analysis of Aβ oligomer-490 
positive neural cell pixel intensity (B) in the CTX, CA1, CA3, DG, and TH at 12 M. EDA 491 
reduces Aβ burdens in APP23 + CCH mice at 12 M. Representative photomicrographs of all 492 
forms of Aβ burdens (C) and quantitative analysis of Aβ burdens areas (D) in the CTX, 493 
hippocampus (HI) and TH at 12 M (**p<0.01 vs WT; ##p<0.01 vs APP23; &&p<0.01 VS 494 
APP23 + CCH. Scale bar=50 µm).   495 
 496 
Fig. 4. EDA attenuates the expression of phosphorylated tau (pTau) in APP23 + CCH mice at 497 
12 M. Representative photomicrographs of pTau (A) and quantitative analysis of pTau-positive 498 
neural cell pixel intensity (B) in the CTX, CA1, CA3, DG, and TH at 12 M (**p<0.01 vs WT; 499 
##p<0.01 vs APP23; &p<0.05 VS APP23 + CCH, &&p<0.01 VS APP23 + CCH. Scale bar=50 500 
µm).   501 
 502 
Fig. 5. EDA ameliorates neural oxidative stress in AD + CCH mice at 12 M. Representative 503 
photomicrographs of 3-NT (A) and AGE (C) in the CTX, CA1, CA3, DG, and TH at 12 M. 504 
Quantitative analysis of 3-NT-positive neural cell pixel intensity (B) and AGE-positive neural 505 
cell pixel intensity (D) in the CTX, CA1, CA3, DG, and TH at 12 M (**p<0.01 vs WT; #p<0.05 506 
vs APP23, ##p<0.01 vs APP23; &p<0.05 VS APP23 + CCH, &&p<0.01 VS APP23 + CCH. 507 
Scale bar=50 µm).   508 
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 509 
Fig. 6. EDA ameliorates neuroinflammation in APP23 + CCH mice at 12 M. Representative 510 
photomicrographs of Iba-1 (A), IL-1β (C), and NLRP3 (E) in the CTX, CA1, CA3, DG, and 511 
TH at 12 M. Quantitative analysis of Iba-1-positive microglia pixel intensity (B), IL-1β-positive 512 
neural cell pixel intensity (D), and NLRP3-positive neural cell pixel intensity (F) in the CTX, 513 
CA1, CA3, DG, and TH at 12 M (*p<0.05 vs WT, **p<0.01 vs WT; #p<0.05 vs APP23, 514 
##p<0.01 vs APP23; &p<0.05 VS APP23 + CCH, &&p<0.01 VS APP23 + CCH. Scale bar=50 515 
µm).    516 
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